Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 17

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 17
---
 his or her family members, and the Company, its senior management and its independent auditors, our Board affirmatively determined that all of our directors, except Ms. Johnson who is not considered independent because she is one of our executive officers, are independent directors as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules.

#### Board Committees
Our Board has a standing audit, compensation, and nominating and corporate governance committee comprised of the directors identified in the table below. Our Board has determined that all committee members are independent under applicable Nasdaq and SEC rules for committee memberships. Each committee operates under a written charter adopted by our Board that sets out its role and responsibilities, a copy of which is available on our website at www.darebioscience.com. Information contained on the website is not incorporated by reference in, or considered part of, this Proxy Statement.

| Director                      |     | Audit |     | Compensation |     | Nominating & Corporate 
 Governance             |
| Jessica D. Grossman, M.D.     |     | M     |     |              |     | M                      |
| Susan L. Kelley, M.D.         |     |       |     |              |     | C                      |
| Sabrina Martucci Johnson      |     |       |     |              |     |                        |
| Gregory W. Matz, CPA          |     | C     |     |              |     | M                      |
| William H. Rastetter, Ph.D.   |     |       |     | C            |     |                        |
| Robin J. Steele, J.D., L.L.M. |     | M     |     | M            |     |                        |
| C = chairperson; M = member   |     |       |     |              |     |                        |

2025 Proxy Statement | Page 10

In addition to the standing committees described above, our Board also has a strategic and pricing committee. Our Board may from time to time delegate and empower the strategic and pricing committee to act on behalf of our Board, except as to matters that by law or our bylaws may not be delegated to a committee of the board of directors of a Delaware corporation, as needed between Board meetings when an accelerated process of Board oversight is necessary or appropriate. When our Board delegates and empowers the strategic and pricing committee to act, the committee meets as necessary, and all of its actions are reported to our Board. The current members of the strategic and pricing committee are Dr.